|
制造商：
akrimax制药
类药物：
交感神经。
活性成分（S）：
盐酸芬特明15毫克，30毫克，37.5mg口服崩解的标签（ODT）的;薄荷味。
指示（S）：
一个短期（数周）基于在管理外源性肥胖的运动，行为修饰和限制热量与初始体重指数≥30kg/m2或≥27kg/m2英寸患者在减重疗程的辅助存在其他危险因素（如高血压，糖尿病，高血脂）。
药理作用：
suprenza是拟交感胺相似，这个类的原型药物用于肥胖，苯丙胺（D-和D / L-苯丙胺）具有药理活性。肥胖在使用这个类药物通常被称为“食欲抑制剂”或“anorexigenics。”它尚未建立，这类药物在治疗肥胖的主要作用是抑制食欲，因为其他中枢神经系统的行动，或者代谢的影响也可以参与。
临床试验：
没有临床研究已进行了与Suprenza。
法律分类：
持续输注
成人：
个性化。使用最低有效剂量。允许解散舌片，然后吞下。 > 16yrs：每天上午通常是一个选项卡。避免迟到下午剂量。
儿童：
≤16yrs：不推荐。
禁忌症（S）：
心血管疾病（如冠状动脉疾病，中风，心律失常，充血性心力衰竭，未控制的高血压）。甲状腺功能亢进症。青光眼。激动的状态。药物滥用史。期间或在14天的单胺氧化抑制剂。怀孕（Cat.X）。哺乳的母亲。
警告/注意事项：
原发性肺动脉高压（PPH）的风险增加，心脏瓣膜病。停止，如果不明原因的呼吸困难，心绞痛，晕厥，或下肢浮肿的发展。停止，如果发生耐受anorectant效果。轻度高血压。糖尿病。肾功能不全。规定最低限度的供应，以避免过量。老人。
互动（补）：
见禁忌。与单胺氧化抑制剂的高血压危象的可能。伴随其他减肥药物，包括SSRIs类药物（氟西汀，舍曲林，氟伏沙明，帕罗西汀）：不推荐。用酒精的注意事项。胰岛素和口服降糖药：可能会被改变的要求。可能会降低肾上腺素能神经元阻断药物的降压作用。
不良反应（S）：
心血管疾病（如PPH，回流心脏瓣膜病，心悸，心动过速，血压升高，缺血性事件，中枢神经系统（如过度兴奋，烦躁不安，头晕，失眠，兴奋，烦躁不安，震颤，头痛，精神病），口干，难闻的味道，胃肠不适，便秘，荨麻疹，阳痿，性欲改变。
如何提供：
的ODT-30，100
Akrimax announced their plans to launch Suprenza (phentermine HCl) orally disintegrating tablets (ODT) as a short-term adjunct in the management of exogenous obesity.
Phentermine HCl is a sympathomimetic amine anorectic indicated for patients with an initial body mass index (BMI) of ≥30kg/m2 or ≥27kg/m2 in the presence of other risk factors (eg, controlled hypertension, diabetes, hyperlipidemia).
Suprenza ODT will be available from Akrimax in 15mg and 30mg dosage strengths in 30- and 100-count bottles.
Manufacturer:
Akrimax Pharmaceuticals
Pharmacological Class:
Sympathomimetic.
Active Ingredient(s):
Phentermine HCl 15mg, 30mg, 37.5mg; orally-disintegrating tabs (ODT); peppermint-flavor.
Indication(s):
A short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥30kg/m2, or ≥27kg/m2 in the presence of other risk factors (eg, hypertension, diabetes, hyperlipidemia).
Pharmacology:
Suprenza is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, amphetamine (d- and d/l-amphetamine). Drugs of this class used in obesity are commonly known as “anorectics’ or “anorexigenics.” It has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects may also be involved.
Clinical Trials:
No clinical studies have been conducted with Suprenza.
Legal Classification:
CIV
Adults:
Individualize. Use lowest effective dose. Allow tablet to dissolve on tongue, then swallow. >16yrs: usually one tab daily in the AM. Avoid late PM dose.
Children:
≤16yrs: not recommended.
Contraindication(s):
Cardiovascular disease (eg, coronary artery disease, stroke, arrhythmias, CHF, uncontrolled hypertension). Hyperthyroidism. Glaucoma. Agitated states. History of drug abuse. During or within 14 days of MAOIs. Pregnancy (Cat.X). Nursing mothers.
Warnings/Precautions:
Increased risk of primary pulmonary hypertension (PPH), valvular heart disease. Discontinue if unexplained dyspnea, angina pectoris, syncope, or lower extremity edema develops. Discontinue if tolerance to anorectant effect occurs. Mild hypertension. Diabetes. Renal impairment. Prescribe minimal supply to avoid overdose. Elderly.
Interaction(s):
See Contraindications. Hypertensive crisis possible with MAOIs. Concomitant other weight loss drugs, including SSRIs (fluoxetine, sertraline, fluvoxamine, paroxetine): not recommended. Caution with alcohol. Insulin and oral hypoglycemics: requirements may be altered. May decrease hypotensive effect of adrenergic neuron blocking drugs.
Adverse Reaction(s):
Cardiovascular (eg, PPH, regurgitant cardiac valvular disease, palpitations, tachycardia, elevated blood pressure, ischemic events, CNS (eg, overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache, psychosis), dry mouth, unpleasant taste, GI upset, constipation, urticaria, impotence, changes in libido.
How Supplied:
ODT—30, 100
Last Updated:
| 
